Show simple item record

dc.contributor.authorTanishka Saraf
dc.contributor.authorYiming Chen
dc.contributor.authorJessica Armstrong
dc.contributor.authorClinton Canal
dc.date2020
dc.date.accessioned2020-06-16T13:24:35Z
dc.date.available2020-06-16T13:24:35Z
dc.identifier.urihttps://hdl.handle.net/10898/12381
dc.description.abstractThis project explores the anticonvulsant potential of lorcaserin in Fragile X Syndrome in which epilepsy prevalence is ~25%. We did a full dose response (1-10 mg/kg) in an audiogenic seizure assay in Fmr1 knock-out mice. Lorcaserin did not affect prevalence at any dose but attenuated seizure severity to some extent.
dc.languageEnglish
dc.subjectAtlanta Research Conference 2020
dc.subjectCollege of Pharmacy
dc.titleExploring 5-HT2 Receptors as Targets for Treating Epilepsy in Fragile X Syndrome: A Preclinical Study of Fmr1 Knock-out Mice
dc.typeText
refterms.dateFOA2020-09-29T13:42:38Z


Files in this item

Thumbnail
Name:
P22_Saraf_T_PHA.pdf
Size:
1.108Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record